Detalhe da pesquisa
1.
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients less than 60 years of age: a prospective phase II study
Haematologica
; 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37941409
2.
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
Blood
; 133(8): 840-851, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30563875
3.
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
Eur J Haematol
; 107(5): 529-542, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34270825
4.
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 21(12): 1630-1642, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33129376
5.
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
BMC Cancer
; 19(1): 504, 2019 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31138244
6.
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
Eur J Haematol
; 103(3): 255-267, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31231828
7.
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Br J Haematol
; 179(4): 586-597, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961309
8.
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
Br J Haematol
; 179(1): 66-74, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28653400
9.
Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.
Haematologica
; 102(8): 1432-1438, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28495913
10.
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
Eur J Haematol
; 99(1): 42-50, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28370401
11.
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.
Haematologica
; 101(7): 839-45, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27036160
12.
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.
Haematologica
; 106(10): 2754-2758, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34092058
13.
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.
Haematologica
; 101(11): 1398-1406, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27662018
14.
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
BMC Cancer
; 16: 290, 2016 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27114074
15.
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.
Ann Hematol
; 95(12): 1931-1942, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27696203
16.
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Haematologica
; 100(7): 964-9, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25840597
17.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Lancet Oncol
; 15(11): 1195-206, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25242045
18.
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Blood
; 119(4): 940-8, 2012 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-22160383
19.
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
Haematologica
; 99(1): 148-54, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23996482
20.
Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO).
Ann Hematol
; 93(7): 1083-95, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24777705